Epistaxis Market to Witness Huge Growth by 2026

Share on facebook
Share on twitter
Share on linkedin
Epistaxis Market Forecast, Trend Analysis & Competition Tracking – Global Market insights 2017 to 2026

The study expects that by the end of 2026, the global epistaxis market will be worth over US$ 230 Mn value, expanding at an estimated 5.2% CAGR during the forecast period, 2017-2026. Key factors driving the sales of epistaxis have been addressed and analyzed in the report. Research shows that common etiologies for epistaxis include blood dyscrasias, consumption of bioreactive medications, arteriovenous malformations, traumatic intubation, orthognathic surgeries, and oncological surgeries. Prevalence of such factors has necessitated the need for first-line medical assistance and management, which is greatly important for minimizing patient morbidity, and in worst cases, mortality. The report has considered several scenarios that project a robust growth in demand for epistaxis medicine in the foreseeable future.

Read Report Summary: https://www.factmr.com/report/344/epistaxis-market

Nosebleed is a common medical condition among the North American population. During their lifetime, more than three-fifth of the population in the US and Canada suffer from epistaxis. Depending on the causative factor, the degree of epistaxis varies from person to person, and robust healthcare infrastructure in the region guarantees the best medical assistance for North Americans suffering from epistaxis. The report estimates that by the end of 2026, the epistaxis market in North America will be worth nearly US$ 90 Mn. The report further projects that the incidence of epistaxis will be considerably high in the Latin American region. Through 2026, Latin America will account for one-fourth revenue share in the global epistaxis market.

Key companies developing drugs on epistaxis have been profiled in the report. Ferring B.V., GlaxoSmithKline PLC, Smith & Nephew Plc., Medline Industries, Inc., Pfizer Inc., Ciron Drugs & Pharmaceuticals Pvt. Ltd., and Bristol-Myers Squibb Co. are expected to remain active in the expansion of the global epistaxis market through 2026.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=344

In several emergency cases, oral doctors and maxillofacial surgeons are being called on in the hospitals to check the common case of nose-bleeding. This condition, medically known as epistaxis, has been one of the common pains for people through the age. Increasing exposure to physical traumas and harsh environment continue to factor the incidence of epistaxis across the globe.

From physical assault to entry of foreign particles, epistaxis can be caused from a range of factors, increasing the need for appropriate and easily available medicine. Manufacturers of drugs are actively developing improved drugs on epistaxis to help people control persistent bleeding from the nose. A recently-published report by Fact.MR projects that in 2017, nearly US$ 150 Mn worth of epistaxis medicine and drugs will be sold across the globe.

For a broader and insightful view of the competition landscape, request for the Sample report: https://www.factmr.com/connectus/sample?flag=S&rep_id=344

About Us

Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.

Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.

The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.

Contact Us

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
E: info@factmr.com
Blog: https://theheraldmedia.com/